Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 21

1.

Determinants of pain in patients with carpal tunnel syndrome.

Nunez F, Vranceanu AM, Ring D.

Clin Orthop Relat Res. 2010 Dec;468(12):3328-32. doi: 10.1007/s11999-010-1551-x. Epub 2010 Sep 1.

2.

Signs and symptoms versus nerve conduction studies to diagnose diabetic sensorimotor polyneuropathy: Cl vs. NPhys trial.

Dyck PJ, Overland CJ, Low PA, Litchy WJ, Davies JL, Dyck PJ, O'Brien PC; Cl vs. NPhys Trial Investigators, Albers JW, Andersen H, Bolton CF, England JD, Klein CJ, Llewelyn JG, Mauermann ML, Russell JW, Singer W, Smith AG, Tesfaye S, Vella A.

Muscle Nerve. 2010 Aug;42(2):157-64. doi: 10.1002/mus.21661.

3.

Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study.

Chibaudel B, Maindrault-Goebel F, Lledo G, Mineur L, André T, Bennamoun M, Mabro M, Artru P, Carola E, Flesch M, Dupuis O, Colin P, Larsen AK, Afchain P, Tournigand C, Louvet C, de Gramont A.

J Clin Oncol. 2009 Dec 1;27(34):5727-33. doi: 10.1200/JCO.2009.23.4344. Epub 2009 Sep 28.

PMID:
19786657
4.

Multi-center assessment of the Total Neuropathy Score for chemotherapy-induced peripheral neurotoxicity.

Cavaletti G, Jann S, Pace A, Plasmati R, Siciliano G, Briani C, Cocito D, Padua L, Ghiglione E, Manicone M, Giussani G; Italian NETox Group.

J Peripher Nerv Syst. 2006 Jun;11(2):135-41.

PMID:
16787511
5.

OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study.

Tournigand C, Cervantes A, Figer A, Lledo G, Flesch M, Buyse M, Mineur L, Carola E, Etienne PL, Rivera F, Chirivella I, Perez-Staub N, Louvet C, André T, Tabah-Fisch I, de Gramont A.

J Clin Oncol. 2006 Jan 20;24(3):394-400.

PMID:
16421419
6.

Oxaliplatin-associated neuropathy: a review.

Cersosimo RJ.

Ann Pharmacother. 2005 Jan;39(1):128-35. Epub 2004 Dec 8. Review.

PMID:
15590869
7.

Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale.

Cavaletti G, Bogliun G, Marzorati L, Zincone A, Piatti M, Colombo N, Parma G, Lissoni A, Fei F, Cundari S, Zanna C.

Neurology. 2003 Nov 11;61(9):1297-300.

PMID:
14610145
8.

Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures.

Gamelin E, Gamelin L, Bossi L, Quasthoff S.

Semin Oncol. 2002 Oct;29(5 Suppl 15):21-33. Review.

PMID:
12422305
9.

Acute oxaliplatin-induced peripheral nerve hyperexcitability.

Wilson RH, Lehky T, Thomas RR, Quinn MG, Floeter MK, Grem JL.

J Clin Oncol. 2002 Apr 1;20(7):1767-74.

PMID:
11919233
10.

Epidermal nerve fiber density in sensory ganglionopathies: clinical and neurophysiologic correlations.

Lauria G, Sghirlanzoni A, Lombardi R, Pareyson D.

Muscle Nerve. 2001 Aug;24(8):1034-9.

PMID:
11439378
11.

Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.

de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A.

J Clin Oncol. 2000 Aug;18(16):2938-47.

PMID:
10944126
12.

Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen.

André T, Bensmaine MA, Louvet C, François E, Lucas V, Desseigne F, Beerblock K, Bouché O, Carola E, Merrouche Y, Morvan F, Dupont-André G, de Gramont A.

J Clin Oncol. 1999 Nov;17(11):3560-8.

PMID:
10550155
13.

Epidermal nerve fiber density: normative reference range and diagnostic efficiency.

McArthur JC, Stocks EA, Hauer P, Cornblath DR, Griffin JW.

Arch Neurol. 1998 Dec;55(12):1513-20.

PMID:
9865794
14.

Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy.

Postma TJ, Heimans JJ, Muller MJ, Ossenkoppele GJ, Vermorken JB, Aaronson NK.

Ann Oncol. 1998 Jul;9(7):739-44.

PMID:
9739440
15.

Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers.

Bécouarn Y, Ychou M, Ducreux M, Borel C, Bertheault-Cvitkovic F, Seitz JF, Nasca S, Nguyen TD, Paillot B, Raoul JL, Duffour J, Fandi A, Dupont-André G, Rougier P.

J Clin Oncol. 1998 Aug;16(8):2739-44.

PMID:
9704726
16.

Small-fiber sensory neuropathies: clinical course and neuropathology of idiopathic cases.

Holland NR, Crawford TO, Hauer P, Cornblath DR, Griffin JW, McArthur JC.

Ann Neurol. 1998 Jul;44(1):47-59.

PMID:
9667592
17.

Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: a phase II multicentric study.

Díaz-Rubio E, Sastre J, Zaniboni A, Labianca R, Cortés-Funes H, de Braud F, Boni C, Benavides M, Dallavalle G, Homerin M.

Ann Oncol. 1998 Jan;9(1):105-8.

PMID:
9541691
18.

Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines.

Machover D, Diaz-Rubio E, de Gramont A, Schilf A, Gastiaburu JJ, Brienza S, Itzhaki M, Metzger G, N'Daw D, Vignoud J, Abad A, Francois E, Gamelin E, Marty M, Sastre J, Seitz JF, Ychou M.

Ann Oncol. 1996 Jan;7(1):95-8.

PMID:
9081400
19.

A prospective study of suramin-induced peripheral neuropathy.

Chaudhry V, Eisenberger MA, Sinibaldi VJ, Sheikh K, Griffin JW, Cornblath DR.

Brain. 1996 Dec;119 ( Pt 6):2039-52.

PMID:
9010008
20.

Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies.

Chaudhry V, Rowinsky EK, Sartorius SE, Donehower RC, Cornblath DR.

Ann Neurol. 1994 Mar;35(3):304-11.

PMID:
7907208

Supplemental Content

Support Center